Trilexium

Trilexium (TRX-E-009-1) is a third-generation of benzopyran structurally related to TRX-E-002-1 (HY-114250) . Trilexium increases p21 protein expression and induces apoptosis. Trilexium depolymerizes microtubules. Trilexium shows broad anti-cancer activity[1][2].

Product Specifications

CAS Number

[1983180-82-0]

Product Name Alternative

TRX-E-009-1

UNSPSC

12352005

Target

Apoptosis; Caspase; Microtubule/Tubulin; PARP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trilexium.html

Purity

99.70

Solubility

DMSO : 300 mg/mL (ultrasonic)

Smiles

OC1=C(OC)C=C([C@H]2[C@@H](C3=CC(F)=C(C=C3)O)C4=CC=C(O)C(C)=C4OC2)C=C1OC

Molecular Formula

C24H23FO6

Molecular Weight

426.43

References & Citations

[1]Stevenson AJ, et al. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Sci Rep. 2018 Mar 23;8 (1) :5144. |[2]Ehteda A, et al. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas. Mol Cancer Ther. 2023 Dec 1;22 (12) :1413-1421.